Progression to cirrhosis in hepatitis C patients: An age-dependent process

Liver International

Volumn 27, Issue 3, 2007, Pages 335-339

  Pradat, Pierre ^a   Voirin, Nicolas ^b   Tillmann, Hans Ludger ^c   Chevallier, Michèle ^d   Trépo, Christian ^a  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d LMM Laboratoire Marcel Merieux   (France)

Author keywords

Age; Cirrhosis; Fibrosis progression; Hepatitis C

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; DISEASE DURATION; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; ONSET AGE; PATIENT MONITORING; PROGNOSIS; SEX DIFFERENCE;

ADULT; AGE OF ONSET; AGED; ALANINE TRANSAMINASE; ALCOHOL DRINKING; BODY MASS INDEX; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 33947240383     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01430.x     Document Type: Article

References (28)

1. Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 2004; 78: 955-63.
2. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish hepatology research group. N Engl J Med 1999; 340: 1228-33.
3. Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. Hepatology 2000; 32: 91-6.
4. Rodger AJ, Roberts S, Lanigan A, et al. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32: 582-7.
5. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132: 105-11.
6. Casiraghi MA, De Paschale M, Romano L, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004; 39: 90-6.
7. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
8. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24 (Suppl.2): 3-8.
9. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The french METAVIR cooperative study group. Hepatology 1994; 20: 15-20.
10. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
11. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
12. Pinzani M, Romanelli RG, Magli S. Progression of fibrosis in chronic liver diseases: Time to tally the score. J Hepatol 2001; 34: 764-7.
13. Minola E, Prati D, Suter F, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002; 99: 4588-91.
14. Murakami C, Hino K, Korenaga M, et al. Factors predicting progression to cirrhosis and hepatocellular carcinoma in patients with transfusion-associated hepatitis C virus infection. J Clin Gastroenterol 1999; 28: 148-52.
15. Matsumura H, Moriyama M, Goto I, et al. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C - a study of 527 patients at one establishment. J Viral Hepat 2000; 7: 268-75.
16. Leone N, Rizzetto M. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 2005; 51: 31-46.
17. Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut 2004; 53: 451-5.
18. Tillmann HL, Manns MP, Rudolph KL. Merging models of hepatitis C virus pathogenesis. Semin Liver Dis 2005; 25: 84-92.
19. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331: 1607-11.
20. Ockenga J, Tillmann HL, Trautwein C, et al. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 1997; 27: 18-24.
21. Pawelec G, Gouttefangeas C. T-cell dysregulation caused by chronic antigenic stress: The role of CMV in immunosenescence? Aging Clin Exp Res 2006; 18: 171-3.
22. Pawelec G, Koch S, Franceschi C, et al. Human immunosenescence: Does it have an infectious component? Ann NY Acad Sci 2006; 1067: 56-65.
23. Charlton M. Recurrence of hepatitis C infection: Where are we now? Liver Transplant 2005; 11: S57-62.
24. Porter SB, Reddy KR. Factors that influence the severity of recurrent hepatitis C virus following liver transplantation. Clin Liver Dis 2003; 7: 603-14.
25. Tillmann HL. Hepatitis C virus infection. N Engl J Med 2001; 345: 1426; author reply 7-8.
26. Fernandez-Rodriguez CM, Gutierrez ML, Serrano PL, et al. Factors influencing the rate of fibrosis progression in chronic hepatitis C. Dig Dis Sci 2004; 49: 1971-6.
27. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International hepatitis interventional therapy group (IHIT). Lancet 1998; 352: 1426-32.
28. Grieve R, Roberts J, Wright M, et al. Cost-effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006; 55: 1332-8.